Awareness and Knowledge of Pharmacists toward Biosimilar Medicines: A Survey in Jordan

Abstract

Aims. Pharmacists in all clinical settings are recognized drug experts and integral educators of biosimilar medicines. Therefore, the objective of this study was to assess pharmacists’ knowledge, predictors of knowledge, and views toward biosimilar medicines in Jordan. Methods. A cross-sectional study was conducted in Jordan during October–December 2020. An Internet-based self-administrated questionnaire on knowledge and views was distributed using social media groups to the pharmacists among different areas in Jordan. A descriptive and univariate analysis was performed. Binary logistic regression was conducted to determine the predictors of knowledge including all variables with p < 0.20 on univariate analysis. Results. A total 536 responses were received, 502 of which were completed (93.7% response rate). A total of 52.6% of the pharmacists were knowledgeable about biosimilar medicines and the mean of knowledge level was 6.47 ± 1.62 (range 2–10). Multivariate analysis identified that respondents who had heard about biosimilars before (OR = 1.942, 95% CI = 1.231–3.063, p < 0.05 ) was more likely to be knowledgeable. Respondents who had not taken the course or the postgraduating training course about biosimilars that were less likely to be knowledgeable (OR = 0.548, 95% CI = 0.357–0.839, p < 0.05 ). A positive response was noted in pharmacist’s view regarding the implementation of biosimilar medicines in healthcare setting, biosimilar medicine prescription related to decreased costs, self-study about biosimilar medicine, and incorporating biosimilar education program at the pharmacy school curriculum universities level. Conclusions. Pharmacists’ views and knowledge vary regarding the particularities and key issues on biosimilar medicines in Jordan. Incorporating biosimilar course in pharmacy school curriculum could improve their acceptance for future pharmacy jobs.

Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region

“…A reluctance to prescribe biosimilars among clinicians in the Middle East has been observed as a result of a limited understanding of biosimilars and a lack of confidence in its efficacy and safety [ 13 , 20 ]. Furthermore, some surveys found that pharmacists lacked adequate information about biosimilars in order to advise patients appropriately [ 38 , 39 ]. Moreover, negative perceptions towards biosimilars can occur among patients because of the misconception that the lower cost of biosimilars is associated with inferior quality and poorer outcomes compared with reference products [ 40 ].…”

Perspective of biopharmaceutics knowledge and practice of pharmacy personnel toward the effect of medication route and medical procedure on nullifying fasting

“…Importantly, pharmacists have biopharmaceutics knowledge ( Oqal et al, 2022 , Shawahna et al, 2022 ) which supposed to qualify their role in enhancing medication treatment outcomes and promoting wellness, through ensuring dispensing and preparing medications in the correct doses and frequency, and counseling patients for safe and appropriate use of medications ( Mansur 2016 ). In fact, health care professionals rely on and trust pharmacists in selecting and administering medications that promote the quality of life for patients, based on their specialized expertise in medication ( Shawahna et al, 2022 ).…”